ITGAM and cancer: In response to the contexts of tissues and diseases, such as inflammatory environment in cancer, monocytes can be recruited to tissues and differentiate into terminal effector cells, such as M2‐like cells in tumor.[113] Inspired by this fact, Hyeon and colleagues developed a new nanoformulation targeting circulating immune cells in blood for enhanced cancer therapy.[114] As illustrated in Figure 11a, anti‐CD11b mAbs conjugated with trans‐cyclooctene (Anti‐CD11b‐TCO) were intravenously injected in mice bearing 4T1 tumor, to target CD11b expressing monocytes circulating in blood.